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Background. Survival after liver transplantation 
has improved significantly over the last decade with 
pediatric recipients faring better than adults. The 20-
year experience of pediatric liver transplantation at 
Children's Hospital of Pittsburgh is reported in terms 
of patient survival; graft survival in relation to age, 
gender, and immunosuppressive protocols; causes of 
death; and indications for retransplantation. 
Method. From March 1981 to April 1998, 808 children 
received liver transplants at Children's Hospital of 
Pittsburgh. All patients were followed until March 
2001, with a mean follow-up of 12.2±3.9 years (medi-
an=12.6; range=2.9-20). There were 405 female (50.2%) 
and 403 male (49.8%) pediatric recipients. Mean age at 
transplant was 5.3±4.9 years (mean=3.3; range 0.04-
17.95), with 285 children (25.3%) being less than 2 years 
of age at transplant. Cyc1osporine (CsA)-based immu-
nosuppression was used before November 1989 in 482 
children (50.7%), and the subsequent 326 recipients 
(40.3%) were treated with tacrolimus-based immuno-
suppression. Actuarial survival was calculated using 
the Kaplan-Meier statistical method. Differences in 
survival were calculated by log-rank analysis. 
Results. Overall patient survival at 1, 5, 10, 15, and 20 
ye*,s was 77.1 %, 72.6%, 69.4%, 65.8%, and 64.4%, respec-
tively. There was no difference in survival for male or 
female patients at any time point. At up to 10 years 
posttransplant, the survival for children greater than 
2 years of age (79.5%, 75.7%, and 71.6% at 1,5, and 10 
years, respectively) was slightly higher than those at 
less than 2 years of age (72.6%, 66.9%, and 65.3% at 1, 5, 
and 10 years, respectively). However, at 15 and 20 
years posttransplant, survival rates were similar (>2 
years=67.3% and 65.8%; <2 years=64.1% and 64.1%). A 
significant difference in survival was seen in CsA-
based immunosuppression (71.2%, 68.1%, 65.4%, and 
61 %) versus tacrolimus-based immunosuppression 
(85.8%,84.7%,83.3%, and 82.90/0) at 1, 3, 5, and 10 years, 
respectively (P=O.OOOI). The maximum difference in 
survival was noted in the first 3 months between CsA 
and tacrolimus; thus, indicating there may have been 
other factors (nonimmunological factors) involved in 
terms of donor and recipient selection and technical 
issues. The mean annual death rate beyond 2 years 
posttransplant was 0.47%, with the mean annual death 
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rate for patients who received tacrolimus-based im-
munosuppression being significantly lower than those 
who received CsA-based immunosuppression (0.14% 
vs. 0.8%; P=O.OOl). The most common etiologies of graft 
loss were hepatic artery thrombosis (33.4%), acute or 
chronic rejection (26.6%), and primary nonfunction 
(16.7%). Of note, retransplantation for graft loss be-
cause of acute or chronic rejection occurred only in 
those patients who received CsA-based immuno-
suppression. 
Conclusion. The overall 20-year actuarial survival 
for pediatric liver transplantation is 64%. Survival has 
increased by 20% in the last 12 years with tacrolimus-
based immunosuppression. Although this improve-
ment may be the result of several factors, retransplan-
tation as a result of acute or chronic rejection has 
been completely eliminated in patients treated with 
tacrolimus. 
Over the past 50 years, advances in organ procurement, 
preservation technology, immunosuppressive management, 
and perioperative care have contributed to the evolution of 
liver transplantation as the treatment of choice for end-stage 
liver disease. Although survival has improved dramatically, 
acute graft loss, chronic rejection, ~stic infections, 
and degenerative diseases have ~g£llDed long-term sur-
vival. Survival for children is signi~ higher than for 
adults (1); however, in the absence of long-term multi-insti-
tutional data, such survival outcomes are difficult to eluci-
date. Consequently, a center-specific 20-year retrospective 
analysis of all pediatric transplant recipients was imple-
mented to determine patient and graft survival, causes of 
graft loss, indications for retransplantation, and differences 
in survival related to age, gender, and immunosuppressive 
protocols. 
MATERIALS AND METHODS 
From March 1981 to April 1998, 808 children received liver trans-
plants at Children's Hospital of Pittsburgh. All patients were fol-
lowed until March 2001, with a mean follow-up of 12.2::!:3.9 years 
(median = 12.6; range=o2.9-20). There were 405 female (50.2%) and 
403 male (49.8%) pediatric recipients. Mean age at transplant was 
5.3:!:4.9 years (mean=3.3; range 0.04-17.95), with 285 children 
(25.3%) less than 2 years of age at transplant. Cyclosporine (CsA)-
based immunosuppression was used before November 1989 in 482 
children (50.7%), and the subsequent 326 recipients (40.3%) were 
treated with tacrolimus·based immunosuppression as previously de-
scribed (2, 3). Indications for liver transplantation are listed in Table 
1. Patients received cadaveric grafts, and living-related grafts were 
not included in the study. Split or reduced-size adult livers were 
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TABLE 1. Indications for liver transplantation 
Indications for liver transplantation CsAn(%) Tacrolimus n( %) 
Biliary atresia 264 (54.7) 153 (46.9) 
Metabolic 77 (15.9) 46 (14.1) 
A-1-A 45 18 
GSD-I 1 0 
GSD-IV 7 5 
Hemochromatosis 2 1 
Hyperlipidemia-II 1 0 
Carbamylphosphatase deficiency 1 1 
Oxalosis 0 7 
Ornithine transcarbamyl 0 3 
deficiency 
Criglar Naiiar syodrome 0 1 
Erythropoetic porphyria 0 1 
Tyrosinemia 10 3 
Wilson's disease 10 6 
ALF 25 (5.1) 25 (7.6) 
NANB hepatitis 24 (4.9) 9(2.7) 
Cryptogenic 15 (3.1) 15 (4.6) 
Familial cholestasis 17 (3.5) 10(3.0) 
Primary hepatic malignancy 11 (2.3) 12 (3.6) 
Neonatal hepatitis 13 (2.6) 7 (2.1) 
Secondary biliary cirrhosis 11 (2.2) 6 (1.8) 
Congenital hepatic fibrosis 5 (1.0) 10(3.1) 
AI hepatitis 4 (0.8) 4(1.2) 
PSC 4(0.8) 3 (0.9) 
HCV 0 2 (0.6) 
Budd-chiari 2 (004) 3 (0.9) 
HBV 1 (0.2) 1 (0.3) 
Others 8 (1.6) 20 (6.1) 
Cystic fibrosis 0 7 
TPN liver failure 2 3 
Nodular regenerative hyperplasia 0 3 
Adenoma 1 0 
Focal nodular hyperplasia 1 0 
Mesenchymal hematoma 1 0 
Pseudoinflammatory tumor 1 0 
Incidental hepatoma 1 0 
Trauma 1 0 
Hemangioma 0 1 
Indian childhood cirrhosis 0 2 
Adrenoleucodystrophy 0 1 
Histiocytosis X 0 1 
Unknown 0 1 
Biliary Dysgenesis 0 1 
Total 482 326 
A-1-A = alpha 1 antitrypsin deficiency; GSD = glycogen storage 
disease; ALF = acute liver failure; NANB = Non-A Non-B; AI = 
autoimmune; PSC = primary sclerosing cholangitis; HCV = hepati-
tis C Virus; HBV = hepatitis B virus; and TPN = total parenteral 
nutrition. 
transplanted in 17 pediatric recipients, all of whom received tacroli-
mus-based immunosuppression. 
Statistical Analysis 
Actuarial survival was calculated with the Kaplan-Meier statisti-
cal method. Differences in survival were calculated by log-rank anal-
ysis. The incidences of various events were compared between two 
groups with the Pearson chi-square. Differences in mean values 
between both groups were compared using the equality of variance 
and independent sample Student t test. The Statistical Package for 
Social Sciences 10.0 software (SPSS, Inc., Chicago, IL) was used for 
generating statistical data. Multiple time points were analyzed to 
study the statistical significance of differences occurring at various 
times during the follow-up period. P<0.05 was considered 
significant. 
RESULTS 
Patient Survival 
Overall patient survival at 1, 5, 10, 15, and 20 years was 
77.1 %,72.6%,69.4%,65.8%, and 64.4%, respectively (Fig. 1). 
There was no difference in survival for male or female pa-
tients at all time points (Fig. 2, top). At up to 10 years 
posttransplant, the survival for children greater than 2 years 
of age (79.5%, 75.7%, and 71.6% at 1, 5, and 10 years, respec-
tively) was slightly higher than those at less than 2 years of 
age (72.6%, 66.9%, and 65.3% at 1, 5, and 10 years, respec-
tively) (Fig. 2, bottom). However, at 15 and 20 years post-
transplant, survival rates were similar (>2 years=67.3% and 
65.8%; <2 years=64.1% and 64.1%). A significant difference 
in survival was seen in CsA-based immunosuppression 
(71.2%,68.1%,65.4%, and 61%) versus tacrolimus-based im-
munosuppression (85.8%, 84.7%, 83.3%, and 82.9%) at 1,3,5, 
and 10 years, respectively (P=O.OOOI) (Fig. 3, top). The max-
imum survival difference was observed in the first 3 months 
posttransplant (22.8% with CsA vs. 9.5% with tacrolimus). 
Mter 3 months, the survival at 10 years was 78.6% with CsA 
versus 91.5% with tacrolimus, a difference of 12.9% (Table 2) 
Causes of Death 
A total of 258 children (32%) died during the follow-up 
period with 55.4% of deaths occurring within the first 3 
months posttransplant. Of the mortalities, 203 recipients 
(42.1%) received CsA-based immunosuppression and 55 re-
cipients (16.8%) were treated with tacrolimus. Causes of 
death are listed in Table 2 with the most common cause of 
death being infection (43%). 
The mean annual death rate beyond 2 years posttrans-
plant was 0.47% with the mean annual death rate for pa-
tients who received tacrolimus-based immunosuppression 
being significantly lower than those who received CsA-based 
immunosuppression (0.14% vs. 0.8%; P=O.OOI) (Table 2). The 
annual death rate for patients using CsA and tacrolimus-
based immunosuppression is shown in Figure 4. The differ-
ence in the death rate between the immunosuppressive pro-
tocols was observed at all time points. The cumulative death 
rate at 1, 3, and 12 months posttransplant for CsA-treated 
patients was 16.3%, 22.6%, and 28.8%, respectively, and for 
tacrolimus-treated patients was 6.4%, 9.5%, and 14%, 
respectively. 
Graft Survival 
Patient deaths or retransplantations were considered as 
graft loss. Graft survival at 1, 5, 10, 15, and 20 years was 
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FIGURE 1. Patient and graft survival over time. 
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FIGURE 3. Patient survival under cyclosporine and tacroli· 
mus immunosuppression. 
66.6%, 60%, 57%, 52.3%, and 37.9%, respectively (Fig. 1). 
There was no difference in graft survival by gender (Fig. 5, 
top). Graft survival for children less than 2 years of age at the 
time of transplant and for those greater than 2 years of age at 
the time of transplant was not significantly different (Fig. 5, 
bottom). Two children under CsA-based immunosuppression 
required late retransplantation for chronic rejection at 16.5 
years and 18 years posttransplant. Graft survival under CsA 
versus tacrolimus-based immunosuppression was similar to 
patient survival with a highly significant difference 
(P=0.0001) at 12 years posttransplant (Fig. 6). 
Indications for Retransplantation 
Two hundred three children (25.1%) required a second 
liver transplant. Additionally, 40 children required a third 
graft, six children received four grafts, and one child received 
five liver transplants. All seven children who received four or 
more grafts died. Hepatic artery thrombosis was the most 
common indication for a second allograft under both esA and 
tacrolimus-based immunosuppression with an incidence of 
33.4% (n=68) (Table 3). The second most common reason for 
Years Post-Transplant 
retransplantation was rejection, both acute and chronic, with 
54 patients (26.6%) who required another graft. Retransplan-
tation was required in six patients (2.9%) with acute rejection 
and in 46 patients (22.6%) with chronic rejection. Interest-
ingly, all retransplantations for acute or chronic rejection 
were performed in patients who were treated with esA-based 
immunosuppression and none under tacrolimus. 
Primary nonfunction was the third most common indica-
tion for retransplantation and was seen in 34 patients 
(16.7%). Of these patients, 19 (9.3%) were treated with CsA 
and 15 (7.3%) were treated with tacrolimus. Additional rea-
sons for retransplantation included biliary stricture, post-
transplant lymphoproliferative disease (PTLD), and others. 
Long-term survival after one retransplantation or 2:2 re-
transplantations was significantly inferior compared to those 
who retained their original allograft (Fig. 7). 
Posttransplant Lymphoproliferative Disease 
PTLD developed in 79 children (9.7%). Of these patients, 
40 children (8.3%) received CsA-based immunosuppression 
and 39 children (11.6%) received tacrolimus-based immuno-
suppression. No significant difference was demonstrated be-
tween groups (P=0.08). The most common site ofPTLD was 
in the lymph nodes. Sites ofPTLD under CsA and tacrolimus 
are shown in Table 4. 
Because most cases of PTLD occur after the first 2 months 
posttransplant, outcomes of patients at risk beyond 2 months 
posttransplant were investigated to further examine the in-
cidence of PTLD. At 2 months posttransplant, 426 patients 
under CsA and 312 patients under tacrolimus were consid-
ered at risk. Of these patients, the incidence of PTLD was 
9.4% in the esA group and 12.5% in the tacrolimus group. 
The difference was not significant (P=0.177). Interestingly, 
survival after PTLD was significantly higher in patients who 
received tacrolimus-based immunosuppression than those 
patients who received CsA (P=0.001) (Fig. 8). 
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TABLE 2. Causes of Death 
Causes Months after transplantation 
Oto3 3to66to12 12 to 24 24 to 36 36 to 48 48 to 60 60 to 72 72 to 84 84 to 96 96 to 108 108 to 120 >120 Total n(%) 
Infections 67 14 7 4 3 5 2 4 1 2 110 (42.6) Cyclosporine 55 10 4 3 1 5 2 4 2 1 Tacrolimus 12 4 3 2 
Cardiovascular 6 2 1 9 (3.4) CycIosporine 3 1 1 
TacroJimus 3 1 
Respiratory 6 2 2 1 11 (4.2) Cyclosporine 5 1 1 1 
Tacrolimus 1 1 1 
Gastrointestinal 5 1 2 1 1 10 (3.8) 
Cyclosporine 2 2 1 1 
Tacrolimus 3 
Central nervous system 5 5 (1.9) 
Cyclosporine 4 
Tacrolimus 1 
Hemorrhage 25 3 1 2 31 (12) 
CycIosporine 21 3 1 2 
Tacrolimus 4 
Recurrent disease 3 1 4 1 1 10 (3.8) 
CycIosporine 3 1 3 1 1 
Tacrolimus 
Other 16 2 4 1 3 1 2 1 1 2 33 (12.7) 
Cyclosporine 12 1 4 1 3 1 2 1 1 2 
Tacrolimus 4 1 
Unknown 10 7 4 2 2 1 2 1 2 6 39 (15.1) 
Cyclosporine 7 3 3 2 2 1 2 1 2 6 
Tacrolimus 3 4 1 1 1 
Total 258 
Mean death rate per year beyond 2 years: overall = 0.47%; under tacrolimus = 0.14%; and under CsA = 0.8%. 
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FIGURE 5. Graft survival by gender (top) and age (bottom). 
TABLE 4. Site of PTLD 
Site ofPTLD CsA Tacrolimus 
Lymph node 17 18 
Tonsil and adenoid 7 
Liver 3 5 
Gastrointestinal 2 12 
Multiple 9 3 
Lung 2 
Spleen 1 
Total (%) 40 (8.3%) 39 (11.65%) 
DISCUSSION 
Long-term survival data from other transplant centers re-
port increased survival over time, which suggested an in-
crease in earlier patient referrals, improvements in surgical 
techniques, improved operative and perioperative patient 
management, and an increased understanding of more po-
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TABLE 3. Indications for retransplantation 
Causes 
Months after transplantation 
Oto3 3to6 6 to 12 12 to 24 24 to 36 36 to 48 48 to 60 60 to 72 72 to 84 84 to 96 96 to 108 108 to 120 >120 Total n(%) 
Hepatic artery thrombosis 68 5 3 1 78 (38.4) 
Cyclosporine 56 3 3 1 
Tacrolimus 12 2 
Primary nonfunction 34 34 (16.7) 
Cyclosporine 19 
Tacrolimus 15 
Acute rejection 5 1 6 (2.9) 
Cyclosporine 5 1 
Tacrolimus None 
Chronic rejection 10 5 5 6 7 3 2 0 2 1 7 48 (23.6) 
Cyclosporine 10 5 5 6 7 3 2 2 1 
Tacrolimus None 
Other* 12 3 3 1 1 1 21 (10.3) 
Cyclosporine 10 2 1 1 1 
Tacrolimus 2 1 2 
Unknown 10 2 1 1 16 (7.8) 
Cyclosporine 9 1 
Tacrolimus 1 2 1 
Total 203 
* = Bilary-3, PTLD-3 Rec-l, and Technical-14. 
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tent immunosuppressive agents (1, 4, 5). Data that reflect 
increased survival after pediatric liver transplantation have 
been reported from the comprehensive European (6) and 
United States (7) registries as well as from individual centers 
including the University of California at Los Angeles (8), 
Dallas (9), Wisconsin (10), and Spain (11) (Table 5). A 20-year 
overall actuarial patient survival of 64.4% is reported here, 
representing the largest pediatric liver transplant experience 
with the longest follow-up from a single center. 
The most significant factor that affects an increased sur-
vival in this experience was a change in immunosuppressive 
protocols from CsA-based immunosuppression in the 1980s, 
with a survival of 61 % at 10 years, to tacrolimus-based im-
munosuppression resulting in an 83% survival at 10 years. 
The highest number of deaths occurred within the first 3 
months posttransplant in each group, but more so in the CsA 
group. Beyond this time, technical and donor/recipient selec-
tion differences are not expected to contribute to the overall 
survival. However, the difference in survival beyond 3 
Years Post-Transplant 
months posttransplant was 13% and still significant, which 
suggests a direct effect of new immunosuppressive agents. 
Another contributing factor was the conversion of several 
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FIGURE 8. Survival after PTLD under cyclosporine and ta-
crolimus immunosuppression. 
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TABLE 5. Improvement in survival over time in other centers 
Transplant centers (ref-year) 
European (ref. 6) 
United States (ref. 7) 
University of California at 
Los Angeles (ref. 8) 
Dallas (ref. 9) 
Wisconsin (ref. 10) 
Spain (ref. 11) 
Pittsburgh (present) 
No. of 
Patients 
2554 
261 
569 
202 
76 
198 
808 
Years 
follow-up 
10 
15 
14 
12 
8 
14 
20 
Survival (%) 
early phase* 
Survival (%) late 
phase* 
58 at 5 years 78 at 5 years 
66.7 at 5 years 
75 at 5 years 85 at 5 years 
72 at 2 years 87 at 2 years 
77.3 at 8 years 
74 at 5 years 82 at 5 years 
61 at 10 years 83 at 10 years 
------------------------------------------------------------------------
* Early phase = in the initial phase of liver transplant; late phase = current results at the time of publication. 
patients who received CsA-based immunosuppression with 
persistent acute cellular rejection or chronic rejection to ta-
crolimus-based therapy (23). 
In the present report, survival after a second or third liver 
transplant is significantly inferior when compared to those 
pediatric recipients who retained their original graft. This 
finding has been supported by other large patient series with 
long-term follow-up (12, 13). Survival for children who re-
ceived a transplant at less than 2 years of age was slightly 
inferior initially when compared to children who received a 
transplant at more than 2 years of age, but survival was 
almost the same in the long term. Comparable results in 
infants have been cited (14-16), although there is an in-
creased risk of hepatic artery thrombosis in this group. 
In previous reports from this center, female liver trans-
plant recipients had an increased survival compared to males 
(1, 17) when the total sample of children and adults was 
analyzed. However, this difference was not observed when 
only the pediatric population was analyzed. 
There are several reports that suggest an immunological 
advantage with tacrolimus compared to CsA (9, 18, 19). 
This analysis reports the complete absence of graft loss 
from either acute or chronic rejection under tacrolimus, 
which is remarkable considering the incidence under CsA 
is 11% in a 20-year follow-up. Migliazza et a1. (11) and 
Asfar et a1. (20) independently found chronic rejection as a 
significant cause of graft loss. Dunn et a1. (12) reported 
that 4% of pediatric deaths after transplantation were 
directly related to rejection. More than a decade ago, ob-
servations from this institution supported the findings of a 
reduced rate of acute rejection as well as a decreased 
severity of rejection in patients who received tacrolimus (3, 
21). Additionally, the ability oftacrolimus to reverse acute 
and chronic rejection and act as a rescue agent for patients 
who fail treatment with CsA provided a better understand-
ing of the process of rejection and its treatment and the 
clinical limits of failure (2, 22). Consequently, a significant 
number of children under CsA-based immunosuppression 
were converted to tacrolimus for ongoing steroid-resistant 
acute and chronic rejection. Many of these children have 
been maintained on much lower doses of steroids (23-25). 
At this institution, nearly 25% of children under CsA-
based immunosuppression have been converted to tacroli-
mus with many of the graft rescued from acute and chronic 
rejection during the last decade (23). Nearly 80% of pedi-
atric patients are now maintained only on low-dose tacroli-
mus. This accomplishment initiated the clinical applica-
tion of steroid-free mono therapy with tacrolimus after 
pediatric liver transplantation (26), which has resulted in 
fewer long-term complications related to steroid use and 
polypharmacological immunosuppressive therapy. 
The virtual absence of chronic rejection in adult liver 
transplant recipients after a review of over 5000 liver biop-
sies from more than 1200 patients with a mean follow-up of 
6 years has been previously reported (27). Hepatitis B and C 
viruses, primary biliary cirrhosis, autoimmune hepatitis, and 
primary sclerosing cholangitis were found to be risk factors 
for the development of chronic rejection after liver transplan-
tation. Fortunately, these liver diseases as indications for 
transplantation are extremely rare in the pediatric popula-
tion. Chronic rejection in pediatric liver transplant recipients 
is usually a result oftreatment for life-threatening infection 
and PTLD or noncompliance. Chronic rejection, as defmed by 
the Banff criteria (28, 29), has not been detected in a subset 
oftacrolimus-treated patients (n=166) with an 8- to 12-year 
follow-up of 500 liver biopsies (Abstract to be presented at 
ILTS 2001). 
PTLD continues to be a complication in pediatric liver 
transplantation. However, the ability to reverse acute rejec-
tion after PTLD coupled with early diagnosis of PTLD 
through serial monitoring of the Epstein Barr viral load in 
high-risk pediatric liver transplant recipients has effectively 
improved survival after PTLD (29). 
The 20-year actuarial survival for pediatric liver trans-
plant recipients is 64% in a series of 808 children. Infection 
remains the most common cause of death. Retransplantation 
is most commonly indicated for hepatic artery thrombosis 
and primary nonfunction. Survival after the introduction of 
tacrolimus-based immunosuppression has increased by 14% 
to 21% at 1 year (85% vs. 71.2%) and 12 years (82.9% vs. 61%) 
posttransplant. The increased survival rate of our program 
may reflect improvements in surgical techniques, better do-
nor/recipient selection, and advance in posttransplant medi-
cal management. However, in our experience, increased sur-
vival can be attributed to the total absence of graft loss as a 
result of acute or chronic rejection by 12-year follow-up, 
which reflects the immunological advantage of tacrolimus-
based immunosuppression. 
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